doi:10.1016/0003-9861(87)90624-2
2123 The Effect of GLP-1RAs on Systemic Inflammation The ability of GLP-1RAs to reduce systemic inflammation (with decreases in hs-C-reactive protein, TNF-, interleukin-6 and interleukin IL-1) has been demonstrated in animal studies, studies on isolated human tissues and RCTs
Comparison of antioxidant activity between green and roasted coffee beans using molecular methods
GLP-1 (glucagon-like peptide-1) agonist medications, such as Ozempic (semaglutide), Victoza (liraglutide), and Byetta (exenatide), have been shown to be effective for weight loss in addition to their primary use for treating type 2 diabetes
References Thakkar K, Billa G
Currently, pharmacological treatments focus primarily on addressing skin photoaging resulting from UV exposure